Yahoo Finance5d
Regeneron Pharmaceuticals, Inc. (REGN): Among the Stocks That Will Go to The Moon According to Analysts
In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. While stocks initially fell based on worries regarding Trump ...
Yahoo Finance6d
Regeneron Pharmaceuticals (REGN): Among the Best Growth Stocks to Invest In According to Analysts
In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best growth stocks to invest in according to analysts. Companies ...
Business Insider13d
Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information – REGN
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the ...
Business Insider9d
Shareholders that lost money on Regeneron Pharmaceuticals, Inc. (REGN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the ...
Bloomberg L.P.6d
Regeneron’s Gene Therapy Improves Hearing in Deaf Children
A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one ...
Morningstar6d
Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts– Hagens Berman
SAN FRANCISCO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is facing headwinds on multiple fronts, including disappointing sales figures, ongoing legal ...
Reuters27d
Regeneron beats quarterly estimates on eczema drug demand; launches dividend program
Feb 4 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and ...
Seeking Alpha14d
Why Regeneron's Price May Soon Break Out
Regeneron Pharmaceuticals (NASDAQ:REGN) is one of the leaders in the ophthalmic disease therapeutics market. In this article, dear Seeking Alpha readers, I present five factors that explain why I ...
Morningstar13d
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report– Hagens Berman
SAN FRANCISCO, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing mounting pressure on multiple fronts. Following disappointing sales figures and ongoing ...
Benzinga.com14d
Looking Into Regeneron Pharmaceuticals's Recent Short Interest
As you can see from the chart above the percentage of shares that are sold short for Regeneron Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall ...
Nasdaq5d
Regeneron Pharmaceuticals Stock: Analyst Estimates & Ratings
Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various serious medical conditions.